Back to News
Market Impact: 0.18
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
Source: globenewswire.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
HUTCHMED announced an exclusive license for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate (ATTC), with expected clinical trial entry in H2 2026. The update is a forward-looking pipeline milestone that modestly improves the company’s development outlook, but it is not near-term commercial/clinical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- What's next for oil refiners after an unprecedented run to all-time highs
- Christine Lagarde: A new age of capital: growth, sovereignty and AI
- US Private Credit Default Rate Hits a Record of 6.3%, Fitch Says
- Siri AI is here as Apple releases iOS 27, macOS Golden Gate and other major OS updates
- Michael Dell is now the fifth richest person in the world—his worth has nearly doubled to $262 billion in the last year alone thanks to AI
- Scholar Rock shares: TD Cowen keeps buy on FDA approval, broad label